VTVT furnishes 8‑K with Q3 2025 financial results press release

Q: Which period do the results cover for VTVT?

The results cover the fiscal quarter ended September 30, 2025 .

Q: Where can I find the detailed results for VTVT?

Details are in the press release filed as Exhibit 99.1 to the 8‑K.

Q: Is the information considered filed or furnished?

The information, including Exhibit 99.1, is furnished , not filed, under the Exchange Act.

Q: Which exchange lists VTVT shares?

VTVT Class A common stock is listed on the Nasdaq Capital Market .

Q: Who signed the report for VTVT?

The report was signed by Paul J. Sekhri , President and Chief Executive Officer.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

vTv Therapeutics Inc. furnished an 8‑K announcing financial results for the fiscal quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, detailing its results.

The report states the information, including Exhibit 99.1, is being furnished and not filed under the Exchange Act, which limits applicability of certain liabilities and incorporation by reference unless specifically cited.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

11/06/2025 - 04:26 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): November 6, 2025

vTv Therapeutics Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-37524	47-3916571
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

3980 Premier Drive, Suite 310

High Point, NC 27265

(Address of principal executive offices)

(336) 841-0300

(Registrant’s telephone number, including area code)

NOT APPLICABLE

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value $0.01 per share	VTVT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

On November 6, 2025, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits


Exhibit No.						Description
99.1						Press Release dated November 6 2025, announcing financial results for the fiscal quarter ended September 30, 2025
104						Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


			VTV THERAPEUTICS INC.

			By:			/s/ Paul J. Sekhri
			Name:			Paul J. Sekhri
			Title:			President and Chief Executive Officer

Dated: November 6, 2025

Source: View Original Filing on SEC EDGAR

FAQ

What did vTv Therapeutics (VTVT) announce in this 8‑K?

The company furnished an announcement of its financial results for the fiscal quarter ended September 30, 2025, via a press release attached as Exhibit 99.1.

Which period do the results cover for VTVT?

The results cover the fiscal quarter ended September 30, 2025.

Where can I find the detailed results for VTVT?

Details are in the press release filed as Exhibit 99.1 to the 8‑K.

Is the information considered filed or furnished?

The information, including Exhibit 99.1, is furnished, not filed, under the Exchange Act.

Which exchange lists VTVT shares?

VTVT Class A common stock is listed on the Nasdaq Capital Market.

Who signed the report for VTVT?

The report was signed by Paul J. Sekhri, President and Chief Executive Officer.